NCT05158023: An ongoing trial by Aslan Pharmaceuticals
This trial is completed, but has been granted a delay in reporting its results.
It must report results 6 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05158023 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 16, 2022 |
| Completion date | June 13, 2023 |
| Required reporting date | June 13, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |